The agreement signed between the company and the university includes two scopes: First, developing a project to implement Convalescent Plasma, which is the first clinical trial of its kind in Colombia as an alternative treatment while a vaccine is developed.

Second, a scope to strengthen national capabilities for local production of chemical and biological reagents, required to detect the disease, without importing them.

The total contribution of ISA in the two projects of this agreement will be COP 1.167 million.

The health emergency caused by the SARS-Cov-2 virus demands without a doubt to take immediate actions, but it also requires a long-term perspective. In fact, to fulfill these two purposes, ISA Gro